Adding age and genetic risk to PSA test could improve screening for prostate cancerBMJ 2012; 345 doi: https://doi.org/10.1136/bmj.e7467 (Published 06 November 2012) Cite this as: BMJ 2012;345:e7467
- Zosia Kmietowicz
Targeting tests for prostate cancer at the men most likely to develop the disease could halve the number needed to be screened, reduce overdiagnosis, and potentially save the NHS millions of pounds, suggests research.
With funding from Cancer Research UK, researchers from London and Cambridge developed a model to estimate the cost and quality adjusted life years (QALYs) of a personalised screening programme compared with an age based screening strategy using data from English cancer registries and the ProtecT study (http://www.hta.ac.uk/1230) into the treatments for clinically localised prostate cancer.
Both strategies used the prostate specific antigen test …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial